Marco Traub

Marco Traub, PhD, currently serves as the Chief Executive Officer of TESCT - The Trans European Stem Cell Therapy Society, where he plays a pivotal role in steering the organization’s strategic vision and operational initiatives. Under his leadership, TESCT has advanced its mission to accelerate the translation of stem cell research into innovative clinical therapies, with a steadfast focus on patient outcomes and quality of life improvements. Dr. Traub’s expertise in molecular diagnostics, gene editing, and biotechnology has been instrumental in fostering collaborative projects that bridge the gap between laboratory discoveries and real-world applications.

In his current role, Marco oversees key projects that leverage cutting-edge stem cell technology and gene editing techniques to develop regenerative therapies for degenerative diseases and other medical conditions. His strategic initiatives include establishing standardized protocols for stem cell manufacturing, promoting cross-border clinical trials, and advocating for policies that facilitate regulatory approval processes within the European Union. As an EU-Commission Expert, he actively contributes to shaping policies that support innovation in regenerative medicine and health economics, ensuring that scientific advancements translate into accessible and effective treatments.

With over two decades of experience in research, management, and education, Marco Traub’s leadership at TESCT exemplifies his commitment to advancing the field of stem cell therapy. His comprehensive understanding of biotechnology, molecular diagnostics, and health economics positions him as a key influencer in the European regenerative medicine landscape, dedicated to improving patient care through scientific excellence and collaborative innovation.